Changchun Huapu Biotechnology Co. Ltd. is a Chinese private company. The firm develops novel therapies for the potential treatment of a variety of cancer indications.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus: NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.

Manufactures pharmaceuticals

Survac ApS specializes in the development of peptide based therapeutic cancer vaccines. It offers the vaccine candidates for licensing and collaboration agreements. The company's vaccine is being examined in clinical phase I & II trials. Survac was founded in 2003 and is located in Hellerup, Denmark

IDEC Pharmaceuticals develop therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases. Idec Pharmaceuticals was founded in 1986 by UC-San Diego physician and immunologist Ivor Royston, San Diego bioentrepreneur Howard Birndorf, and Stanford University cancer researchers Ron Levy and Richard Miller. In 2003, Idec Pharmaceuticals was merged with Biogen.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Acambis Research Ltd. is a British joint venture company located in Reading that engages in research and experimental development on natural sciences and engineering. It was founded in 1992.

MMRGlobal, Inc. provides secure and web-based storage solutions. The company serves consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. Its product portfolio comprises of MyMedicalRecords, MyEsafeDepositBox, MMRPatientView and MMRPro. The company was founded in 2000 and is headquartered in Los Angeles, CA.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.